Agilent Technologies is scheduled to report fiscal second-quarter 2026 results on May 27, 2026. Wall Street consensus calls for earnings per share of $1.41 and revenue of approximately $1.80 billion.
MDXH shares are plummeting approximately 41% in premarket trading on May 14, 2026, following a Q1 2026 earnings release after the May 13 close that contained several significant negative disclosures. Primary catalyst: MDxHealth announced it is discontinuing its Resolve UTI business due to an uncertain reimbursement environment, eliminating a meaningful revenue stream and triggering a full strategic pivot.
GeneDx Holdings ( WGS ) shares plunged 48.54% to close at $34.95, following the previous close of $67.93. Primary catalyst: Q1 2026 earnings miss with EPS of -$0.28 versus expected -$0.06, and revenue of $102.3 million missing consensus of $112.5 million.
Medpace Holdings (MEDP) shares are trading down approximately 22% in pre-market on April 23, 2026, from a prior close of $508.46, implying a pre-market price near $397. The primary catalyst is a sub-1.0 net book-to-bill ratio of 0.88x in Q1 2026 — a closely watched metric that signals new bookings fell short of recognized revenue, raising concerns about future backlog growth and revenue sustainability.
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets.
For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics.
Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
The medical companies segment has experienced a notable increase in performance, recording a weekly gain of +3.53%. This sector encompasses companies involved in the production and supply of pharmaceuticals and essential medical products, catering to a broad spectrum of healthcare needs. Their product offerings include surgical apparel, gloves, hospital furniture, fluid management solutions, and specialized equipment for cosmetic and surgical procedures.
Recently, Women's Health companies have taken center stage, showcasing a remarkable +14.83% increase in performance over the past week. This surge is backed by three key players in the sector - AWH (Aspira Women's Health), AGRX (Agile Therapeutics), and RDUS (Radius Health). Today, stocks in the Women's Health group maintain a positive outlook, supported by robust Volume Indicators.
In the world of biopharmaceutical companies specializing in surgeries and treatments for diseases like solid tumors, cancers, and hematologic malignancies, a select group of stocks has been making waves.
For the Physicians group companies, which include DYNT (Dynatronics), ANGO (AngioDynamics), AMEH (Apollo Medical Holdings), and OPRX (OptimizeRx), the past week has been marked by a significant increase in performance, with a collective gain of +4.41%. However, a deeper look into various indicators and metrics suggests a challenging road ahead for these stocks.
The Vascular sector has been making waves in the financial markets, with a remarkable surge of 27.39% in performance over the past week. This impressive performance has piqued the interest of investors and analysts alike. In this article, we will delve into this exciting theme and explore the group of tickers driving this growth. From positive momentum indicators to notable price movements and volume surges, we'll dissect the factors contributing to this sector's success.
The Vascular group of tickers has recently made waves by recording a staggering +252.11% increase in performance over just one day. This remarkable surge has garnered significant attention from investors and traders alike, prompting a closer examination of the theme and the individual tickers within it.
The Diabetes sector has been making headlines recently with a remarkable surge in performance, recording an impressive +11.13% increase over the past week. This surge has sparked considerable interest among investors and analysts alike. In this article, we'll delve into the details of this theme, focusing on the four key tickers that have been at the forefront of this trend: NURO, DRIO, ORGS, and DMAC.
The non-invasive sector encompasses manufacturers dedicated to the development of noninvasive biological response-activating devices. Companies like NanoVibronix Inc. are at the forefront, innovating medical products using low-intensity acoustic technology.
Discover a winning strategy for swing trading with sector rotation. Utilizing both technical and fundamental analysis, our expert Swing Trader generates an impressive 7.12% return for IDXX. Don't miss out on the momentum indicator turning positive, signaling a promising upward trend for IDXX stock.
Discover the power of our Swing Trader's Sector Rotation Strategy combining Technical & Fundamental Analysis (TA&FA). This unique approach has achieved impressive 14.2% returns for Month-To-Date (MTD). Our stock may rebound from the lower band, heading toward the middle band. It's time to consider buying the stock or exploring call options for potential profit maximization.
WAT's RSI Indicator exits the oversold zone as of June 12, 2023, indicating a potential trend reversal from downward to upward. Historical data of 23 similar instances reveals 16 resulted in a price hike - a 70% chance of success. Utilize our swing trading sector rotation strategy for enhanced returns.
Discover how our AI Trading Bot achieved impressive gains of 41.54% for SDC. Get insights into the top high-volatility stocks with our Swing Trader: Top High-Volatility Stocks v.2 (TA) tool. Mark your calendars for SDC's upcoming earnings report on Aug 07, 2023
Our AI Trading Bot has generated a 4.50% gain for swing traders in popular stocks. This innovative tool uses advanced algorithms to analyze both technical and fundamental aspects of the market. The earnings report for 'A' is expected on Aug 15, 2023. Discover the power of AI in trading today. gain for swing traders in popular stocks. This innovative tool uses advanced algorithms to analyze both technical and fundamental aspects of the market. The earnings report for 'A' is expected on Aug 15, 2023. Discover the power of AI in trading today.
Discover how our AI Trading Bot has generated a remarkable 15.27% gain in WAT stocks. Perfect for beginners and experts alike, our bot excels in trending down markets. Stay tuned for the upcoming earnings report on Aug 01, 2023. Explore the power of AI in stock trading today.